Regeneron Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 03, 2022 at 06:30 am EDT
Share
Regeneron Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 2,936.2 million compared to USD 3,452.8 million a year ago. Net income was USD 1,315.7 million compared to USD 1,632.2 million a year ago. Basic earnings per share from continuing operations was USD 12.31 compared to USD 15.37 a year ago. Diluted earnings per share from continuing operations was USD 11.66 compared to USD 14.33 a year ago.
For the nine months, revenue was USD 8,758.5 million compared to USD 11,120 million a year ago. Net income was USD 3,141.3 million compared to USD 5,846.3 million a year ago. Basic earnings per share from continuing operations was USD 29.3 compared to USD 55.42 a year ago. Diluted earnings per share from continuing operations was USD 27.73 compared to USD 52.29 a year ago.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
REGENERON PHARMACEUTICALS, INC. 
